NeoGenomics Q3 Results: Revenue Up 11.9%, EPS Beats Expectations.

NeoGenomics (NEO) shares rose 1.1% after Q3 2025 revenue beat expectations at $187.8 million, up 11.9% YoY. The company's adjusted EPS of $0.03 also surpassed forecasts of $0.02. Despite a negative operating margin, investors focused on the strong top-line performance, signaling confidence in the company's trajectory. The shares cooled down to $10.16, up 0.1% from the previous close.